- Home
- ROOT vs SNDX Comparison
ROOT vs SNDX Comparison
Compare ROOT & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- SNDX
- Stock Information
- Founded
- ROOT 2015
- SNDX 2005
- Country
- ROOT United States
- SNDX United States
- Employees
- ROOT N/A
- SNDX N/A
- Industry
- ROOT Property-Casualty Insurers
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- ROOT Finance
- SNDX Health Care
- Exchange
- ROOT Nasdaq
- SNDX Nasdaq
- Market Cap
- ROOT 1.1B
- SNDX 1.1B
- IPO Year
- ROOT 2020
- SNDX 2016
- Fundamental
- Price
- ROOT $75.91
- SNDX $13.11
- Analyst Decision
- ROOT Buy
- SNDX Strong Buy
- Analyst Count
- ROOT 9
- SNDX 10
- Target Price
- ROOT $58.13
- SNDX $36.20
- AVG Volume (30 Days)
- ROOT 307.4K
- SNDX 2.9M
- Earning Date
- ROOT 02-19-2025
- SNDX 02-25-2025
- Dividend Yield
- ROOT N/A
- SNDX N/A
- EPS Growth
- ROOT N/A
- SNDX N/A
- EPS
- ROOT N/A
- SNDX N/A
- Revenue
- ROOT $1,044,599,999.00
- SNDX $16,000,000.00
- Revenue This Year
- ROOT N/A
- SNDX N/A
- Revenue Next Year
- ROOT $8.98
- SNDX N/A
- P/E Ratio
- ROOT N/A
- SNDX N/A
- Revenue Growth
- ROOT 215.11
- SNDX N/A
- 52 Week Low
- ROOT $7.22
- SNDX $12.40
- 52 Week High
- ROOT $118.15
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- ROOT 42.73
- SNDX 38.83
- Support Level
- ROOT $72.47
- SNDX $12.40
- Resistance Level
- ROOT $81.34
- SNDX $14.65
- Average True Range (ATR)
- ROOT 4.62
- SNDX 0.61
- MACD
- ROOT 0.15
- SNDX 0.19
- Stochastic Oscillator
- ROOT 37.79
- SNDX 31.56
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. The company is a direct-to-consumer personal auto insurance, renters insurance and mobile technology company. It generates revenue from the sale of auto insurance policies within the United States.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.